Globus Medical, Inc. (NYSE:GMED) Shares Sold by Global Alpha Capital Management Ltd.

Global Alpha Capital Management Ltd. trimmed its position in Globus Medical, Inc. (NYSE:GMED - Free Report) by 7.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 819,391 shares of the medical device company's stock after selling 65,750 shares during the period. Globus Medical makes up approximately 4.9% of Global Alpha Capital Management Ltd.'s investment portfolio, making the stock its 3rd largest holding. Global Alpha Capital Management Ltd. owned 0.60% of Globus Medical worth $67,772,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC grew its position in Globus Medical by 2.5% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 5,637 shares of the medical device company's stock valued at $403,000 after purchasing an additional 140 shares in the last quarter. Stephens Inc. AR boosted its position in Globus Medical by 3.4% during the third quarter. Stephens Inc. AR now owns 4,229 shares of the medical device company's stock valued at $303,000 after purchasing an additional 138 shares during the last quarter. Farther Finance Advisors LLC grew its stake in Globus Medical by 230.5% in the third quarter. Farther Finance Advisors LLC now owns 552 shares of the medical device company's stock valued at $39,000 after purchasing an additional 385 shares in the last quarter. Van ECK Associates Corp increased its position in shares of Globus Medical by 36.1% during the 3rd quarter. Van ECK Associates Corp now owns 62,505 shares of the medical device company's stock worth $4,618,000 after purchasing an additional 16,583 shares during the last quarter. Finally, Crossmark Global Holdings Inc. raised its stake in shares of Globus Medical by 6.0% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 7,750 shares of the medical device company's stock worth $554,000 after purchasing an additional 436 shares in the last quarter. 95.16% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling at Globus Medical

In other news, CFO Keith W. Pfeil sold 14,167 shares of the stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $88.29, for a total value of $1,250,804.43. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 18.54% of the company's stock.

Globus Medical Trading Down 3.1 %

NYSE GMED traded down $2.29 during midday trading on Wednesday, hitting $71.20. The company had a trading volume of 2,468,988 shares, compared to its average volume of 1,330,533. The company has a market capitalization of $9.79 billion, a PE ratio of 94.93, a P/E/G ratio of 1.61 and a beta of 1.19. Globus Medical, Inc. has a twelve month low of $49.33 and a twelve month high of $94.93. The firm has a 50-day moving average price of $85.57 and a 200-day moving average price of $79.82.

Globus Medical (NYSE:GMED - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The medical device company reported $0.84 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.10. The business had revenue of $657.29 million during the quarter, compared to analysts' expectations of $646.19 million. Globus Medical had a net margin of 4.09% and a return on equity of 10.83%. On average, equities analysts anticipate that Globus Medical, Inc. will post 3.44 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have commented on GMED. Roth Mkm increased their price target on shares of Globus Medical from $100.00 to $115.00 and gave the company a "buy" rating in a research note on Tuesday, December 17th. Needham & Company LLC reiterated a "hold" rating on shares of Globus Medical in a report on Friday, February 21st. Morgan Stanley raised Globus Medical from an "equal weight" rating to an "overweight" rating and boosted their price target for the stock from $83.00 to $100.00 in a research report on Monday, December 2nd. Bank of America raised Globus Medical from an "underperform" rating to a "neutral" rating and raised their price objective for the company from $80.00 to $97.00 in a research report on Thursday, January 9th. Finally, StockNews.com cut Globus Medical from a "buy" rating to a "hold" rating in a research note on Wednesday, March 5th. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $97.82.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.